SHILPA SAMBASHIVAN, PhD

Shilpa Sambashivan is the Chief Executive Officer and a member of the Board of Directors of Nura Bio. She previously served as the company’s Chief Scientific Officer. As the founding scientific leader at the company, Shilpa led the establishment of Nura Bio’s bespoke R&D engine and its differentiated small molecule pipeline. Prior to joining Nura Bio, Shilpa spent almost a decade at Amgen and NGM Biopharmaceuticals across disease areas spanning neurodegeneration, neuroinflammation and metabolism. In addition to defining R&D strategy, Shilpa has led both small and large molecule drug discovery programs from early target discovery through preclinical biomarker development and first-in-human testing.  

Shilpa graduated with honors with an undergraduate degree in Biological Sciences from the Birla Institute of Science and Technology in India. She earned her graduate degree in Molecular Biology and Protein Biochemistry from UCLA, where she conducted research on elucidating the molecular basis of protein misfolding in neurodegenerative diseases in the lab of Professor David Eisenberg. Shilpa was also a Bio-X Genentech Foundation postdoctoral fellow at Stanford University.